Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

754 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL, Rodríguez-Belenguer P, Caballero D, Martino R, Lopez-Corral L, Terol MJ, Vazquez L, Calabuig M, Sanz-Linares G, Marin-Jimenez F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual MJ, Rodriguez-Fernandez A, Olave MT, Cascales-Hernandez A, Gago B, Hernández-Rivas JÁ, Villalon L, Corona M, Roldán-Pérez A, Ribes-Amoros J, González-Santillana C, Garcia-Sanz R, Navarro D, Serrano-López AJ, Cedillo Á, Soria-Olivas E, Sureda A, Solano C; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Piñana JL, et al. Among authors: ferrer e. Ann Hematol. 2022 Sep;101(9):2053-2067. doi: 10.1007/s00277-022-04906-8. Epub 2022 Jul 2. Ann Hematol. 2022. PMID: 35780254 Free article.
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Piñana JL, López-Corral L, Martino R, Montoro J, Vazquez L, Pérez A, Martin-Martin G, Facal-Malvar A, Ferrer E, Pascual MJ, Sanz-Linares G, Gago B, Sanchez-Salinas A, Villalon L, Conesa-Garcia V, Olave MT, López-Jimenez J, Marcos-Corrales S, García-Blázquez M, Garcia-Gutiérrez V, Hernández-Rivas JÁ, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer-Lores B, Guerreiro M, Ruiz-García M, Muñoz-Bellido JL, Navarro D, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC). Piñana JL, et al. Among authors: ferrer lores b, ferrer e. Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2. Am J Hematol. 2022. PMID: 34695229 Free PMC article.
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Among authors: ferrer e. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.
Castellanos M, Cinza Z, Dorta Z, Veliz G, Vega H, Lorenzo I, Ojeda S, Dueñas-Carrera S, Alvarez-Lajonchere L, Martínez G, Ferrer E, Limonta M, Linares M, Ruiz O, Acevedo B, Torres D, Márquez G, Herrera L, Arús E. Castellanos M, et al. Among authors: ferrer e. J Gene Med. 2010 Jan;12(1):107-16. doi: 10.1002/jgm.1407. J Gene Med. 2010. PMID: 19866482 Clinical Trial.
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group. Jaén A, et al. Among authors: ferrer e. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20. doi: 10.1097/qai.0b013e31815ee282. J Acquir Immune Defic Syndr. 2008. PMID: 18297762
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.
Lejeune M, Miró JM, De Lazzari E, García F, Claramonte X, Martínez E, Ribera E, Arrizabalaga J, Arribas JR, Domingo P, Ferrer E, Plana M, Valls ME, Podzamczer D, Pumarola T, Jacquet A, Mallolas J, Gatell JM, Gallart T; Spanish Toxoplasma gondii Study Group. Lejeune M, et al. Among authors: ferrer e. Clin Infect Dis. 2011 Mar 1;52(5):662-70. doi: 10.1093/cid/ciq197. Clin Infect Dis. 2011. PMID: 21292671
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. Among authors: ferrer e. Clin Infect Dis. 2015 Mar 1;60(5):811-20. doi: 10.1093/cid/ciu898. Epub 2014 Nov 10. Clin Infect Dis. 2015. PMID: 25389256 Free article. Clinical Trial.
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration. Lodi S, et al. Among authors: ferrer e. Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7. Lancet HIV. 2015. PMID: 26423376 Free PMC article.
When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. Caniglia EC, et al. Among authors: ferrer e. J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):214-21. doi: 10.1097/QAI.0000000000000956. J Acquir Immune Defic Syndr. 2016. PMID: 26895294 Free PMC article.
754 results